Russell Investments Group
AIMT

Russell Investments Group’s Aimmune Therapeutics AIMT Stock Holding History

Russell Investments Group’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-55,502
Closed -$927K – 3304
2020
Q2 		$927K Buy
55,502
+6,168
+13% +$105K ﹤0.01% 2099
2020
Q1 		$710K Buy
+49,334
New +$1.26M ﹤0.01% 2009
2019
Q1 		– Sell
-25,614
Closed -$612K – 3071
2018
Q4 		$612K Buy
25,614
+363
+1% +$9.39K ﹤0.01% 2227
2018
Q3 		$690K Buy
25,251
+6,215
+33% +$176K ﹤0.01% 2259
2018
Q2 		$513K Hold
19,036
– – ﹤0.01% 2384
2018
Q1 		$605K Sell
19,036
-13,341
-41% -$469K ﹤0.01% 2414
2017
Q4 		$1.25M Sell
32,377
-34,077
-51% -$1.1M ﹤0.01% 2037
2017
Q3 		$1.65M Buy
66,454
+40,557
+157% +$874K ﹤0.01% 1893
2017
Q2 		$532K Sell
25,897
-6,682
-21% -$127K ﹤0.01% 2386
2017
Q1 		$708K Sell
32,579
-50,757
-61% -$1.04M ﹤0.01% 2281
2016
Q4 		$1.71M Buy
+83,336
New +$1.7M ﹤0.01% 1889

Other funds holding AIMT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Russell Investments Group's AIMT Position: Q3 2020 in Review

Russell Investments Group sold out of Aimmune Therapeutics (AIMT) in Q3 2020, closing a stake of 55,502 shares — an estimated $927K sold.

Russell Investments Group first reported a position in AIMT in Q4 2016 and held it in 11 quarters. The position peaked at $1.71M in Q4 2016. 188 funds tracked by Wall St. Rank hold AIMT as of Q3 2020.

  • Russell Investments Group reported no remaining Aimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Russell Investments Group sold 55,502 Aimmune Therapeutics shares in Q3 2020, an estimated $927K.
  • Russell Investments Group first reported a position in Aimmune Therapeutics in Q4 2016 and held it in 11 quarters.
  • Russell Investments Group's Aimmune Therapeutics position peaked at $1.71M in Q4 2016.
  • 188 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2020.

Based on Russell Investments Group's 13F filing for Q3 2020, filed 9 Nov 2020.